000009219 001__ 9219
000009219 005__ 20240415103425.0
000009219 0247_ $$2DOI$$a10.6083/8w32r639w
000009219 037__ $$aIR
000009219 245__ $$aPrimary Imatinib resistance in PDGFRA-mutant GIST
000009219 260__ $$bOregon Health and Science University
000009219 269__ $$a2021
000009219 336__ $$aAbstract
000009219 520__ $$aGastrointestinal stromal tumor (GIST) is the most common sarcoma of the GI tract. The second most common type of GIST is driven by oncogenic mutations in PDGFRA, of which there are 50+ different kinase domain mutations reported. 82% of these occur in the kinase activation loop (AL), with the majority being a single point mutation, D842V. PDGFRA-D842V is notoriously resistant to conventional tyrosine kinase inhibitors approved for GIST, including imatinib. However, it isn't known how GIST with other PDGFRA AL mutations, which include numerous complex indels, would clinically respond to imatinib.
000009219 540__ $$fCC BY
000009219 542__ $$fIn copyright - joint owners
000009219 650__ $$aSarcoma$$025711
000009219 650__ $$aImatinib Mesylate$$011313
000009219 650__ $$aProtein Kinase Inhibitors$$035962
000009219 650__ $$aDrug Resistance$$018079
000009219 650__ $$aGastrointestinal Stromal Tumors$$035784
000009219 6531_ $$acancer
000009219 6531_ $$aneoplasms
000009219 7001_ $$aKhosroyani, Homma M.$$uOregon Health and Science University$$041354
000009219 7001_ $$aKlug, Lillian$$uOregon Health and Science University$$041354
000009219 7001_ $$aHeinrich, Michael$$uOregon Health and Science University$$041354
000009219 711__ $$aResearch Week$$uOregon Health and Science University$$d2021
000009219 8564_ $$99bdd9b7d-b51e-42c0-baa4-eb73b0c9e72c$$s166489$$uhttps://digitalcollections.ohsu.edu/record/9219/files/Khosroyani-Homma-OHSU-ResearchWeek-2021.pdf
000009219 905__ $$a/rest/prod/8w/32/r6/39/8w32r639w
000009219 980__ $$aResearch Week